EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

Li Hu, Houyong Li, Xicai Sun iD, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang iD

International Forum of Allergy & Rhinology · 2026-11 · 16 (11) · 1309-1317

DOI: 10.1002/alr.70208 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 29.07.2026. Verfasst von Li Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Eye & ENT Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinitis, Rhinosinusitis. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese patients with CRSwNP.

Methods

Adult patients with severe CRSwNP were randomized 1:1 to tezepelumab (210 mg) or placebo for 52 weeks. Co‐primary endpoints were changes from baseline at Week 52 (W52) in total nasal‐polyp score and bi‐weekly mean nasal‐congestion score. Key secondary endpoints included changes from baseline in Nasal Polyposis Symptom Diary (NPSD) loss‐of‐smell score, 22‐item Sinonasal Outcome Test (SNOT‐22) total score, Lund–Mackay score, NPSD total symptom score, and time to first nasal‐polyp surgery decision and/or systemic glucocorticoid use.

Results

Twenty‐nine patients received tezepelumab, and 34 received placebo. At W52, tezepelumab achieved numerically greater improvements in total nasal‐polyp score (least‐squares mean difference vs. placebo [95% CI]: −2.03 [−2.88, −1.19]) and bi‐weekly mean nasal‐congestion score (−0.72 [−1.23, −0.21]). Compared with placebo, tezepelumab also improved NPSD loss‐of‐smell score (−0.44 [−0.82, −0.06]), SNOT‐22 total score (−16.34 [−29.80, −2.88]), Lund–Mackay score (−5.30 [−7.23, −3.38]), and NPSD total symptom score (−3.76 [−6.89, −0.63]). No tezepelumab‐treated patients required nasal‐polyp surgery or systemic glucocorticoids.

Conclusion

Consistent with the overall population, tezepelumab reduced nasal‐polyp size and improved loss‐of‐smell and other sinonasal symptoms in Chinese patients with CRSwNP, with a favorable safety profile. No surgery or systemic glucocorticoids were required. These benefits were observed despite relatively lower baseline eosinophil counts in these patients. Further investigation is warranted to assess the generalizability to the broader Chinese population with CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNasal PolypsRhinitisRhinosinusitisSinusitisAdultFemaleHumansMaleMiddle AgedChinaChronic DiseaseDouble-Blind MethodTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Chinesebiologicschronic rhinosinusitis with nasal polypstezepelumab

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Eye & ENT Hospital of Fudan University, Shanghai, China.
  • Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
  • Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
  • Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • BioPharmaceuticals R&D, Respiratory & Immunology Biometrics & Statistical Innovation, AstraZeneca, Gaithersburg, Maryland, USA.
  • Global Development, Amgen, Thousand Oaks, California, USA.

ORCID-Profile: Xicai Sun, Dehui Wang

Förderung

  • AstraZeneca
  • Amgen

Zitieren

APA

Hu, L., Li, H., Sun, X., Liu, Q., Xu, Y., Fan, J., Foster, A., Chen, C., Chon, Y., & Wang, D. (2026). Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial. International Forum of Allergy & Rhinology, 16(11), 1309-1317. https://doi.org/10.1002/alr.70208

Vancouver

Hu L, Li H, Sun X, Liu Q, Xu Y, Fan J, et al. Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial. International Forum of Allergy & Rhinology. 2026;16(11):1309-1317. doi:10.1002/alr.70208

BibTeX
@article{Hu2026,
  author = {Hu, Li and Li, Houyong and Sun, Xicai and Liu, Quan and Xu, Yu and Fan, Jiangang and Foster, Andrew and Chen, Claudia and Chon, Yun and Wang, Dehui},
  title = {Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial},
  journal = {International Forum of Allergy & Rhinology},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {1309--1317},
  doi = {10.1002/alr.70208}
}
Kostenlos starten →